PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma
AbstractBackground:Targeted therapies with BRAF plus MEK inhibitors (BRAFi; MEKi)represent the major treatment strategy for patients with BRAF-mutated metastatic melanoma(MM). Previous analyses suggested a correlation between programmed death-ligand 1 (PD-L1)expression in tumour tissues and the outc...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2018
|
| In: |
European journal of cancer
Year: 2017, Volume: 88, Pages: 67-76 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2017.10.026 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1016/j.ejca.2017.10.026
|
| Author Notes: | Katrin Schaper-Gerhardt, Steven Okoyea, Rudolf Herbst, Jens Ulrich, Patrick Terheyen, Claudia Pfö̈hler, Jochen S. Utikal, Alexander Kreuter, Peter Mohr, Edgar Dippel, Imke Satzger, Antje Sucker, Dirk Schadendorf, Selma Ugurel, Ralf Gutzmera |
| Summary: | AbstractBackground:Targeted therapies with BRAF plus MEK inhibitors (BRAFi; MEKi)represent the major treatment strategy for patients with BRAF-mutated metastatic melanoma(MM). Previous analyses suggested a correlation between programmed death-ligand 1 (PD-L1)expression in tumour tissues and the outcome of targeted therapies. This study investigatedPD-L1 as a potential predictive biomarker of BRAFi-based targeted therapies in MM patients |
|---|---|
| Item Description: | Gesehen am 28.05.2019 Available online 28 November 2017 |
| Physical Description: | Online Resource |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2017.10.026 |